Design and methods of European Ambulance Acute Coronary Syndrome Angiography Trial (EUROMAX): An international randomized open-label ambulance trial of bivalirudin versus standard-of-care anticoagulation in patients with acute ST-segment-elevation myocardial infarction transferred for primary percutaneous coronary intervention

American Heart Journal

Volumn 166, Issue 6, 2013, Pages

  Steg, Philippe Gabriel ^a,b,c   Van'T Hof, Arnoud ^d   Clemmensen, Peter ^e   Lapostolle, Frédéric ^f,g,h   Dudek, Dariusz ⁱ   Hamon, Martial ^j   Cavallini, Claudio ^k,l   Gordini, Giovanni ^l   Huber, Kurt ^m   Coste, Pierre ⁿ   Thicoipe, Michel ^o   Nibbe, Lutz ^p   Steinmetz, Jacob ^q   Ten Berg, Jurrien ^r   Eggink, Gerrit Jan ^s   Zeymer, Uwe ^t   Campo Dell'Orto, Marco ^u   Kanic, Vojko ^v   Deliargyris, Efthymios N ^w   Day, Jonathan ^x   Schuette, Diana ^x   Hamm, Christian W ^u   Goldstein, Patrick ^y   more..

^a UNIVERSITÉ PARIS DESCARTES   (France)

^b INSERM   (France)

^c BICHAT HOSPITAL   (France)

^d ISALA HOSPITAL   (Netherlands)

^e UNIVERSITY OF COPENHAGEN   (Denmark)

^f SAMU 93 UF Recherche Enseignement Qualité   (France)

^g AVICENNE HOSPITAL   (France)

^h UNIVERSITÉ PARIS 13   (France)

ⁱ JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

^j UNIVERSITÉ DE CAEN   (France)

^k SANTA MARIA DELLA MISERICORDIA HOSPITAL   (Italy)

^l MAGGIORE HOSPITAL   (Italy)

^m WILHELMINEN HOSPITAL   (Austria)

ⁿ UNIVERSITÉ DE BORDEAUX   (France)

^o BORDEAUX UNIVERSITY HOSPITAL   (France)

^p CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^q Rigshospitalet   (Denmark)

^r ST ANTONIUS HOSPITAL   (Netherlands)

^s RAV IJsselvecht   (Netherlands)

^t KLINIKUM LUDWIGSHAFEN   (Germany)

^u KERCKHOFF HEART CENTER   (Germany)

^v UNIVERSITY MEDICAL CENTRE MARIBOR   (Slovenia)

^w MEDICINES COMPANY   (United States)

^x Diagnostica Stago   (United Kingdom)

^y LILLE UNIVERSITY HOSPITAL   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; CLOPIDOGREL; ENOXAPARIN; EPTIFIBATIDE; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; HIRULOG; PRASUGREL; TICAGRELOR; TIROFIBAN; ANTICOAGULANT AGENT; ANTITHROMBIN; ANTITHROMBOCYTIC AGENT; HIRUDIN DERIVATIVE; PEPTIDE FRAGMENT; RECOMBINANT PROTEIN;

ADULT; AMBULANCE; ANTICOAGULATION; ARTICLE; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; DAY HOSPITAL; DRUG DOSE REDUCTION; FEMALE; FOLLOW UP; HEALTH CARE QUALITY; HEART INFARCTION; HEART LEFT BUNDLE BRANCH BLOCK; HOSPITAL DISCHARGE; HUMAN; INTENTION TO TREAT ANALYSIS; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; OPEN STUDY; OUTCOME ASSESSMENT; PATIENT TRANSPORT; PERCUTANEOUS CORONARY INTERVENTION; PRACTICE GUIDELINE; PRIORITY JOURNAL; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; RECOMMENDED DRUG DOSE; ST SEGMENT DEPRESSION; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; T WAVE; BLEEDING; CHEMICALLY INDUCED; CLINICAL TRIAL; COMPARATIVE STUDY; MULTICENTER STUDY; MYOCARDIAL INFARCTION; PROCEDURES; TREATMENT OUTCOME;

AMBULANCES; ANTICOAGULANTS; ANTITHROMBINS; FEMALE; HEMORRHAGE; HEPARIN; HIRUDINS; HUMANS; MALE; MYOCARDIAL INFARCTION; PATIENT TRANSFER; PEPTIDE FRAGMENTS; PERCUTANEOUS CORONARY INTERVENTION; PLATELET AGGREGATION INHIBITORS; RECOMBINANT PROTEINS; TREATMENT OUTCOME;

EID: 84888638493     PISSN: 00028703     EISSN: 10976744     Source Type: Journal    
DOI: 10.1016/j.ahj.2013.08.025     Document Type: Article

References (43)

1. P.G. Steg, S.K. James, and D. Atar ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation Eur Heart J 33 2012 2569 2619
2. P.T. O'Gara, F.G. Kushner, and D.D. Ascheim 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines Circulation 127 2013 529 555
3. G.W. Stone, B. Witzenbichler, and G. Guagliumi Bivalirudin during primary PCI in acute myocardial infarction N Engl J Med 358 2008 2218 2230
4. R. Mehran, A.J. Lansky, and B. Witzenbichler Bivalirudin in patients undergoing primary angioplasty for acute myocardial infarction (HORIZONS-AMI): 1-year results of a randomised controlled trial Lancet 374 2009 1149 1159
5. G.W. Stone, B. Witzenbichler, and G. Guagliumi Heparin plus a glycoprotein IIb/IIIa inhibitor versus bivalirudin monotherapy and paclitaxel-eluting stents versus bare-metal stents in acute myocardial infarction (HORIZONS-AMI): final 3-year results from a multicentre, randomised controlled trial Lancet 377 2011 2193 2204
6. M.B. Kadakia, N.R. Desai, and K.P. Alexander Use of anticoagulant agents and risk of bleeding among patients admitted with myocardial infarction: a report from the NCDR ACTION Registry-GWTG (National Cardiovascular Data Registry Acute Coronary Treatment and Intervention Outcomes Network Registry-Get With the Guidelines) JACC Cardiovasc Interv 3 2010 1166 1177
7. M. Sejersten, S.L. Nielsen, and T. Engstrom Feasibility and safety of prehospital administration of bivalirudin in patients with ST-elevation myocardial infarction Am J Cardiol 103 2009 1635 1640
8. Dangas GD, Caixeta A, Mehran R, et al. Frequency and predictors of stent thrombosis after percutaneous coronary intervention in acute myocardial infarction. Circulation;123:1745-56.
9. N. von Beckerath, D. Taubert, and G. Pogatsa-Murray Absorption, metabolization, and antiplatelet effects of 300-, 600-, and 900-mg loading doses of clopidogrel: results of the ISAR-CHOICE (Intracoronary Stenting and Antithrombotic Regimen: Choose Between 3 High Oral Doses for Immediate Clopidogrel Effect) Trial Circulation 112 2005 2946 2950
10. P. Capranzano, and G. Dangas Bivalirudin for primary percutaneous coronary intervention in acute myocardial infarction: the HORIZONS-AMI trial Expert Rev Cardiovasc Ther 10 2012 411 422
11. C. Kimmelstiel, P. Zhang, and N.K. Kapur Bivalirudin is a dual inhibitor of thrombin and collagen-dependent platelet activation in patients undergoing percutaneous coronary intervention Circ Cardiovasc Interv 4 2011 171 179
12. G.W. Stone, B.T. McLaurin, and D.A. Cox Bivalirudin for patients with acute coronary syndromes N Engl J Med 355 2006 2203 2216
13. S.D. Wiviott, E. Braunwald, and C.H. McCabe Prasugrel versus clopidogrel in patients with acute coronary syndromes N Engl J Med 357 2007 2001 2015
14. L. Wallentin, R.C. Becker, and A. Budaj Ticagrelor versus clopidogrel in patients with acute coronary syndromes N Engl J Med 361 2009 1045 1057
15. G. Montalescot, S.D. Wiviott, and E. Braunwald Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial Lancet 373 2009 723 731
16. P.G. Steg, S. James, and R.A. Harrington Ticagrelor versus clopidogrel in patients with ST-elevation acute coronary syndromes intended for reperfusion with primary percutaneous coronary intervention: A Platelet Inhibition and Patient Outcomes (PLATO) trial subgroup analysis Circulation 122 2010 2131 2141
17. P.G. Steg, R.A. Harrington, and H. Emanuelsson Stent thrombosis with ticagrelor versus clopidogrel in patients with acute coronary syndromes: an analysis from the prospective randomized PLATO trial Circulation 128 2013 1055 1065
18. M. Valgimigli, M. Tebaldi, and G. Campo Prasugrel versus tirofiban bolus with or without short post-bolus infusion with or without concomitant prasugrel administration in patients with myocardial infarction undergoing coronary stenting: the FABOLUS PRO (Facilitation through Aggrastat By drOpping or shortening Infusion Line in patients with ST-segment elevation myocardial infarction compared to or on top of PRasugrel given at loading dOse) trial JACC Cardiovasc Interv 5 2012 268 277
19. D. Alexopoulos, G. Dimitropoulos, and P. Davlouros Prasugrel overcomes high on-clopidogrel platelet reactivity post-stenting more effectively than high-dose (150-mg) clopidogrel: the importance of CYP2C19*2 genotyping JACC Cardiovasc Interv 4 2011 403 410
20. S.R. Mehta, S.S. Jolly, and J. Cairns Effects of radial versus femoral artery access in patients with acute coronary syndromes with or without ST-segment elevation J Am Coll Cardiol 60 2012 2490 2499
21. E. Romagnoli, G. Biondi-Zoccai, and A. Sciahbasi Radial versus femoral randomized investigation in ST-segment elevation acute coronary syndrome: the RIFLE-STEACS (Radial Versus Femoral Randomized Investigation in ST-Elevation Acute Coronary Syndrome) study J Am Coll Cardiol 60 2012 2481 2489
22. F. Van de Werf, J. Bax, and A. Betriu Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation: The Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology Eur Heart J 29 2008 2909 2945
23. G. Montalescot, U. Zeymer, and J. Silvain Intravenous enoxaparin or unfractionated heparin in primary percutaneous coronary intervention for ST-elevation myocardial infarction: the international randomised open-label ATOLL trial Lancet 378 2011 693 703
24. A.W. Van't Hof, J. Ten Berg, and T. Heestermans Prehospital initiation of tirofiban in patients with ST-elevation myocardial infarction undergoing primary angioplasty (On-TIME 2): a multicentre, double-blind, randomised controlled trial Lancet 372 2008 537 546
25. U. Zeymer The role of eptifibatide in patients undergoing percutaneous coronary intervention Expert Opin Pharmacother 8 2007 1147 1154
26. S.G. Goodman, V. Menon, and C.P. Cannon Acute ST-segment elevation myocardial infarction: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition) Chest 133 2008 708S 775S
27. S. Evans When and how can endpoints be changed after initiation of a randomized clinical trial? PLoS Clin Trials 2 2007 e18
28. J. Wittes On changing a long-term clinical trial midstream Stat Med 21 2002 2789 2795
29. P. Gao, J.H. Ware, and C. Mehta Sample size re-estimation for adaptive sequential design in clinical trials J Biopharm Stat 18 2008 1184 1196
30. E.G. Bovill, M.L. Terrin, and D.C. Stump Hemorrhagic events during therapy with recombinant tissue-type plasminogen activator, heparin, and aspirin for acute myocardial infarction. Results of the Thrombolysis in Myocardial Infarction (TIMI), Phase II Trial Ann Intern Med 115 1991 256 265
31. The GUSTO investigators An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction N Engl J Med 329 1993 673 682
32. D.E. Cutlip, S. Windecker, and R. Mehran Clinical end points in coronary stent trials: a case for standardized definitions Circulation 115 2007 2344 2351
33. G. De Luca, C.M. Gibson, and F. Bellandi Early glycoprotein IIb-IIIa inhibitors in primary angioplasty (EGYPT) cooperation: an individual patient data meta-analysis Heart 94 2008 1548 1558
34. K. Huber, P.E. Aylward, and A.W.J. van 't Hof Glycoprotein IIb/IIIa inhibitors before primary percutaneous coronary intervention of ST-elevation myocardial infarction improve perfusion and outcome: insights from APEX-AMI Circulation 116 2007 673 (abstract)
35. P. Ortolani, A. Marzocchi, and C. Marrozzini Long-term effectiveness of early administration of glycoprotein IIb/IIIa agents to real-world patients undergoing primary percutaneous interventions: results of a registry study in an ST-elevation myocardial infarction network Eur Heart J 30 2009 33 43
36. J. Dong, G. Ndrepepa, and C. Schmitt Early resolution of ST-segment elevation correlates with myocardial salvage assessed by Tc-99m sestamibi scintigraphy in patients with acute myocardial infarction after mechanical or thrombolytic reperfusion therapy Circulation 105 2002 2946 2949
37. R. Schroder, R. Dissmann, and T. Bruggemann Extent of early ST segment elevation resolution: a simple but strong predictor of outcome in patients with acute myocardial infarction J Am Coll Cardiol 24 1994 384 391
38. A.W. van 't Hof, A. Liem, and M.J. de Boer Clinical value of 12-lead electrocardiogram after successful reperfusion therapy for acute myocardial infarction. Zwolle Myocardial infarction Study Group Lancet 350 1997 615 619
39. M.G. McLaughlin, G.W. Stone, and E. Aymong Prognostic utility of comparative methods for assessment of ST-segment resolution after primary angioplasty for acute myocardial infarction: the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) trial J Am Coll Cardiol 44 2004 1215 1223
40. B.R. Brodie, T.D. Stuckey, and C. Hansen Relation between electrocardiographic ST-segment resolution and early and late outcomes after primary percutaneous coronary intervention for acute myocardial infarction Am J Cardiol 95 2005 343 348
41. K. Schroder, K. Wegscheider, and U. Zeymer Extent of ST-segment deviation in a single electrocardiogram lead 90 min after thrombolysis as a predictor of medium-term mortality in acute myocardial infarction Lancet 358 2001 1479 1486
42. C.E. Buller, Y. Fu, and K.W. Mahaffey ST-segment recovery and outcome after primary percutaneous coronary intervention for ST-elevation myocardial infarction: insights from the Assessment of Pexelizumab in Acute Myocardial Infarction (APEX-AMI) trial Circulation 118 2008 1335 1346
43. G. De Luca, A.C. Maas, and H. Suryapranata Prognostic significance of residual cumulative ST-segment deviation after mechanical reperfusion in patients with ST-segment elevation myocardial infarction Am Heart J 150 2005 1248 1254